Breaking News

CompleCure, AGC Biologics Partner to Develop Advanced Anti-Cancer Therapy

AGC to develop the manufacturing process for a novel anti-cancer therapeutic, which uses Antibody Mimetics Drug Conjugate technology.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

AGC Biologics, a global biopharmaceutical CDMO, entered into a strategic service agreement with CompleCure to develop the manufacturing process for a novel anti-cancer therapeutic, which uses Antibody Mimetics Drug Conjugate (AMDC) technology—an advancement in cancer treatment.    AGC Biologics is developing the manufacturing process for the protein component of this new therapeutic at its facility in Chiba, Japan. The AMDC technology represents a significant evolution of Antibody Drug Conjuga...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters